Peachtree Corners
Peachtree Corners
Peachtree Corners, Georgia, United States21 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Recruiting | Phase 3 | 2026-10-05 | NCT07619118 | |
| A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Active, not recruiting | Phase 3 | 2026-10-05 | NCT06894212 | |
| A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Heart Murmurs, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Systolic Murmurs, cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Phase 2 | 2026-10-02 | NCT07142356 | |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-02 | NCT06283966 | |
| Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT05968430 | |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT07114874 | |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection | Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Hepadnaviridae infectious disease, Infections, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 1 | 2026-09-25 | NCT07024641 | |
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Recruiting | Phase 3 | 2026-09-10 | NCT07619131 | |
| Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Recruiting | Phase 2 | 2026-09-02 | NCT07028749 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism | autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Not yet recruiting | Phase 3 | 2026-08-24 | NCT07284745 | |
| A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-08-24 | NCT07000357 | |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-13 | NCT06309966 | |
| A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT07000123 | |
| A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | Heterozygous Familial Hypercholesterolaemia | Active, not recruiting | Phase 3 | 2026-07-16 | NCT07000136 | |
| Long-term Safety and Tolerability of BHV-7000 | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Enrolling by invitation | Phase 2 | 2026-05-01 | NCT06443463 | |
| ALTO-207 in Adults With Treatment-resistant Depression (TRD) | Depressive Disorder, Treatment-Resistant, depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-04-28 | NCT07553637 | |
| Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Tourette syndrome, basal ganglia disorder, brain disorder, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, neurodevelopmental disorder, psychiatric disorder, tic disorder | Active, not recruiting | Phase 2 | 2026-03-09 | NCT06315751 | |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-01-20 | NCT06633016 | |
| Randomized Withdrawal Study in Patients With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-01-12 | NCT06961968 | |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) | Bipolar Disorder I or II With a Major Depressive Episode | Recruiting | Phase 2 | 2025-07-16 | NCT06656416 |